Lenvatinib plus pembrolizumab for the treatment of patients with non-BRAF mutated anaplastic thyroid cancer: A single center, phase 2 clinical trial.

Eur J CancerAug 26, 2026 (epub)
Clinical ResearchOncology (Medical)

Maria E Cabanillas, Naifa L Busaidy, Mark Zafereo et al.

✦ AI-curated · Sources linked

In 30 seconds

This phase 2 clinical trial evaluated the efficacy of lenvatinib plus pembrolizumab in 25 patients with non-BRAF mutated anaplastic thyroid cancer (ATC). The study found a median overall survival (OS) of 13 months, significantly improving upon the historical median OS of 3 months with lenvatinib alone.

Key findings

  • Median overall survival was 13 months (95% CI: 7.8-35.6; p<0.01).
  • Median progression-free survival was 5.4 months (95% CI: 3.8-11.0).
  • The best overall response rate in target lesions was 36%, including 1 complete and 8 partial responses.

Why it matters

The study highlights a potential treatment option for patients with non-BRAF mutated ATC, a group historically facing limited effective therapies. Improved survival outcomes may influence treatment strategies in this challenging population.

Source

PubMed · PMID 42673705

Published in Eur J Cancer. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.